Q-linea (QLINEA) investor relations material

Executive summary

• Shipped five ASTar instruments in Q2 2026, expanding the installed base and commercial pipeline to 24 contracted units, up from 12 a year ago.

• Achieved FDA clearance for an expanded ASTar menu in the U.S., enhancing competitive positioning and driving increased commercial activity.

• Completed four new distribution agreements in new international markets, with first placements in Asia expected in H2 2026 and more partners in the pipeline.

• Significant improvement in year-over-year operating income due to cost reduction programs, site consolidation, and reorganization.

Financial highlights

• Net sales reached SEK 1.5 million in Q2 2026, up from SEK 500,000 in Q2 2025, mainly driven by consumable revenue.

• Consumable revenue totaled SEK 1.3 million, stable sequentially.

• Operating result improved to -SEK 31.3 million from -SEK 47.4 million year-over-year.

• Cash flow from operations was -SEK 30.1 million in Q2, including a SEK 5 million prepayment for inventory.

• Net cash position at quarter-end was SEK 186.8 million.

Outlook and guidance

• Expectation of new market entries, additional contracted customers, and increased consumables demand in H2 2026.

• Operating expenses projected to remain below SEK 11 million per month for H2 2026.

• Continued focus on cost discipline, capital recovery, and gross margin expansion.

• Anticipated launch of a new non-blood isolate test in Q3 2026.

• Cash and short-term investments expected to cover operational needs for the next 12 months.